Explore Our Personalized Weight Loss Program Options In addition to core medical weight loss programs, InjectCo offers several physician-guided options to accommodate different preferences and care needs
References Alshammari N, Platts JA
In November 2023, the MHRA issued updated guidance emphasizing that these treatments shouldnt be combined under any circumstances
When selecting a treatment regimen, consider factors such as cardiovascular and renal comorbidities, drug efficacy and adverse effects, hypoglycemic risk, presence of overweight or obesity, cost, access, and patient preferences
Shaman AM, Bain SC, Bakris G et al (2022) Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER
The most common reported effect is a 3060-second sting from the copper-peptide complex